Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.
about
Wilms tumor 1 mutations in the pathogenesis of acute myeloid leukemiaMonitoring minimal residual disease in acute myeloid leukaemia: a review of the current evolving strategiesActive specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trialsASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management.Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical ApplicationsAdvancing the Minimal Residual Disease Concept in Acute Myeloid LeukemiaMeasurable residual disease testing in acute myeloid leukaemia.Evaluation of BM cytomorphology after allo-SCT in patients with AML.Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse.The Wilms' tumor (WT1) gene expression correlates with the International Prognostic Scoring System (IPSS) score in patients with myelofibrosis and it is a marker of response to therapy.Quantitative assessment of Wilms tumor 1 expression by real-time quantitative polymerase chain reaction in patients with acute myeloblastic leukemiaMinimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?Development of standardized approaches to reporting of minimal residual disease data using a reporting software package designed within the European LeukemiaNet.Primary refractory acute myeloid leukaemia - in search of better definitions and therapies.Molecular characterization of the rare translocation t(3;10)(q26;q21) in an acute myeloid leukemia patientAnalysis of CLLU1 expression levels before and after therapy in patients with chronic lymphocytic leukemia.Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse.Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccinationMinimal residual disease in acute myeloid leukaemiaLymphodepletion is permissive to the development of spontaneous T-cell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemotShortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin.The European LeukemiaNet: achievements and perspectives.Prognostically important molecular markers in cytogenetically normal acute myeloid leukemia.Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies.Detection and preliminary characterization of CD8+T lymphocytes specific for Wilms' tumor antigen in patients with non-Hodgkin lymphoma.Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses.Single nucleotide polymorphisms in the Wilms' tumour gene 1 in clear cell renal cell carcinomaWT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children's oncology groupNew strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine.Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantationOverexpression of Wilms tumor 1 gene as a negative prognostic indicator in acute myeloid leukemiaHypoxia-sensitive epigenetic regulation of an antisense-oriented lncRNA controls WT1 expression in myeloid leukemia cellsCurrent Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia.A multigene array for measurable residual disease detection in AML patients undergoing SCTThe Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia: New Insights Based on a Survey of 44 CasesComparative analysis of different approaches to measure treatment response in acute myeloid leukemiaMinimal residual disease detection in pediatric acute myeloid leukemia: does flow cytometry score a point over molecular biology?Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients.
P2860
Q26744111-417DA03C-87B3-4511-BE6C-2B493C2DE824Q26770394-5C547F9E-8BF3-4BFA-8382-02BE8801C3B1Q27026836-06E4343A-0E2B-45B0-B8C6-BECED059B679Q27851679-EEA3111E-C876-4C65-BAFB-F02109C23531Q27851694-139A56D8-41F5-4658-A30C-A328A5BB9D47Q28073464-997E1B85-0404-4664-9D30-FBE435DF1B53Q28087291-39E0D575-BB15-49CB-AFEE-CE4C65A5F550Q30234914-540413C1-DAB7-482C-B01C-F7FD8234AEBBQ30318110-8E46FA36-8704-4A58-8131-DB3DEB09F788Q33412354-C1883DFE-305A-4DE5-B5B8-47F81DFF3730Q33432158-19887BC5-0C06-43B5-9747-514B9FDB1882Q33660751-CB5B928C-E9E7-428F-9A0E-975AC461C711Q33832709-908B1A11-1695-40A5-B756-362267F9CAB4Q33873297-378CFDDA-6B2F-49ED-A404-CE7110C23FEBQ33877213-5D91D21A-3DB9-4CB0-8615-99D68A16DC14Q33960024-17FEC57B-9630-45D3-910F-59001BB77C9AQ33965688-595C0927-65B2-4A8F-B132-1B57417B7C8FQ33978907-637A2938-F88B-46DE-8A97-7C6DE049D011Q34068404-29E04F92-82D9-4F9A-A514-BFCA42D51533Q34179265-55900B2C-E257-4629-8BFF-49A74ECACA17Q34180369-023DDEC7-901A-4316-B3E1-1083B7027F31Q34193514-55831091-CF46-4505-9969-92934A417B98Q34227693-DD1FD22C-A864-4358-A0FA-B718CBDADCD4Q34451619-FBC9A7DA-6328-4823-B7D6-D8546A87CFBEQ34522735-C6E7E4B9-5FFC-4E87-AB3B-1033B676587DQ34612637-A5019504-E462-4C43-A84C-67E8C6E0555AQ34616701-9895940E-B75F-4421-8D84-B2C9CABA566FQ34617770-F5111515-AC07-4DD1-8D36-FB0622273E09Q34618828-F26E3A80-E390-43BE-98C3-23DE151BF638Q34667832-0F81274B-CA70-46DC-A316-860B9FC0BB40Q34715598-D0CF3BAB-B665-4D58-8D91-C7C8B3BFA838Q34861985-84DBFF90-AEDD-413F-9F80-CCE6494A5986Q35130976-037F5CE9-AC3E-4345-B3FC-DDFF55F19DD8Q35203507-5D4D91A5-59CB-449D-963A-711F8CEFE015Q35546759-1AAF3A10-C14E-45AE-9A41-877015738107Q35582360-1F3C043E-1194-4A17-8B21-75008239EBFAQ36008991-85CD6A4E-9331-47C4-9490-914E6CFC2540Q36290737-3E8B6B3F-564F-4170-A5AA-373CA3A21C9CQ36508284-3E164620-7AB3-4AC6-8082-1A2B400E2FBCQ36528379-984C42D8-3581-4921-958B-2C2FB7E8D33C
P2860
Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Real-time quantitative polymer ...... a European LeukemiaNet study.
@en
Real-time quantitative polymer ...... a European LeukemiaNet study.
@nl
type
label
Real-time quantitative polymer ...... a European LeukemiaNet study.
@en
Real-time quantitative polymer ...... a European LeukemiaNet study.
@nl
prefLabel
Real-time quantitative polymer ...... a European LeukemiaNet study.
@en
Real-time quantitative polymer ...... a European LeukemiaNet study.
@nl
P2093
P50
P356
P1476
Real-time quantitative polymer ...... a European LeukemiaNet study.
@en
P2093
Adrian van der Heijden
Aline Renneville
Barbara Izzo
Bert A van der Reijden
Claude Preudhomme
Daniela Cilloni
David Grimwade
Enrico Gottardi
Fabienne Hermitte
Jelena V Jovanovic
P304
P356
10.1200/JCO.2009.22.4865
P407
P577
2009-09-14T00:00:00Z